GLPG1690 is a selective autotaxin inhibitor discovered by Galapagos, with potential application in idiopathic pulmonary disease (IPF). In a Phase 1 study in healthy human volunteers, GLPG1690 demonstrated favorable safety and tolerability, as well as a strong pharmacodynamic signal implying target engagement. Galapagos is conducting a Phase 2 study FLORA in IPF. The study is fully recruited and topline results are expected in H2 2017. GLPG1690 is fully proprietary to Galapagos.